| Title |
Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine (Cervarix®): A Guide to Its Two-Dose Schedule in Girls Aged 9–14 Years in the EU
|
|---|---|
| Published in |
Pediatric Drugs, March 2014
|
| DOI | 10.1007/s40272-014-0071-7 |
| Pubmed ID | |
| Authors |
Katherine A. Lyseng-Williamson |
| Abstract |
A two-dose vaccination schedule for the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is approved for the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types in girls aged 9-14 years in countries in the EU and elsewhere. In this patient population, the two-dose schedule elicited a high immunogenic response that matched that of the three-dose schedule in women aged 15-25 years and, therefore, was inferred to provide clinical protection against oncogenic HPV cervical infection and, consequently, against precancerous lesions and cervical cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 6% |
| Unknown | 15 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 5 | 31% |
| Librarian | 3 | 19% |
| Lecturer > Senior Lecturer | 1 | 6% |
| Other | 1 | 6% |
| Student > Bachelor | 1 | 6% |
| Other | 2 | 13% |
| Unknown | 3 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 44% |
| Agricultural and Biological Sciences | 3 | 19% |
| Immunology and Microbiology | 1 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 6% |
| Unknown | 4 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 October 2014.
All research outputs
#15,329,366
of 23,573,357 outputs
Outputs from Pediatric Drugs
#394
of 563 outputs
Outputs of similar age
#128,072
of 225,236 outputs
Outputs of similar age from Pediatric Drugs
#3
of 5 outputs
Altmetric has tracked 23,573,357 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 563 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 225,236 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.